Silvia Escribano Serrat Explores A Potential Role of EASIX as a Predictor of Refractoriness and Mortality in iTTP
Silvia Escribano Serrat, Research Fellow at Memorial Sloan Kettering Cancer Center, shared on LinkedIn:
”I am pleased to share this multicenter article on the potential role of EASIX as a predictor of refractoriness and mortality in iTTP.”
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a severe thrombotic microangiopathy caused by profound ADAMTS13 deficiency; although caplacizumab speeds platelet recovery, about 15% of patients remain refractory and may experience persistent endothelial or microvascular injury.
This study assessed whether the Endothelial Activation and Stress Index (EASIX) can track endothelial dysfunction and predict refractoriness or mortality in iTTP.
Read the full article here.
Article: EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura
Authors: Silvia Escribano Serrat, María Queralt Salas, Cristina Pascual-Izquierdo, Manuel Fernández Villalobos, Inés Gómez-Seguí, Teresa Fidalgo, Marta Fernández Docampo, Jorge Martínez Nieto, Óscar Lamas, Miquel Lozano, Joan Cid, Paola Charry, Marc Pino, Patricia Molina, Blanca De Moner, Álex Ramos, Ana Belén Moreno-Castaño, Julia Martínez-Sánchez, Ginés Escolar, Maribel Díaz-Ricart
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!